Table 1Pharmacokinetics, indications, and dosing of included drugs28, 29, 33, 34

Drug
Trade Name
Indications Labeled by the U.S. Food and Drug AdministrationDosing Recommended by the U.S. Food and Drug Administration
Pegylated interferon alfa-2a
Pegasys®
Patients 5 years of age and older with chronic HCV infection with compensated liver disease not previously treated with interferon alfa180 mcg once weekly in combination with ribavirin for 24 weeks with ribavirin for genotypes 2 or 3, or 48 weeks for genotype 1or 4 infection
Pegylated interferon alfa-2b
PEG-Intron®
Patients 5 years of age and older with chronic HCV infection with compensated liver disease1.5 mcg/kg weekly in combination with ribavirin for 24 weeks with ribavirin for genotypes 2 or 3, or 48 weeks for genotype 1 infection
Boceprevir
Victrelis®
Adults with chronic HCV genotype 2 infection with compensated liver disease, including cirrhosis, who are previously untreated or who have been previously treated with interferon and ribavirin therapyFour weeks of treatment with pegylated interferon (alfa-2a or 2b) plus ribavirin, then the addition of boceprevir 800 mg 3 times daily as follows:a

In treatment-naïve patients without cirrhosis:
-

If HCV-RNA undetectable from treatment week 8 through week 24, complete triple therapy at treatment week 28

-

If HCV-RNA detectable at treatment week 8 and undetectable at treatment week 24, continue triple therapy through treatment week 36 and continue pegylated interferon (alfa-2a or 2b) with ribavirin through treatment week 48

In treatment-naïve patients with cirrhosis:
-

44 weeks of triple therapy

Telaprevir
Incivek®
Adults with chronic HCV genotype 1 infection with compensated liver disease, including cirrhosis, who are previously untreated or who have been previously treated with interferon and ribavirin therapy750 mg 3 times a day with pegylated interferon (alfa-2a or 2b) and ribavirin for all patients for 12 weeks, followed by response-guided regimen of pegylated interferon and ribavirina

In treatment-naïve patients without cirrhosis:
-

If HCV-RNA is undetectable at weeks 4 and 12, then continue dual therapy for 12 more weeks (total treatment 24 weeks)

-

If HCV-RNA is detectable at week 4 and/or week 12, then continue dual therapy for 36 more weeks (total treatment 48 weeks)

In treatment-naïve with cirrhosis:
-

Continue dual therapy for 36 more weeks (total treatment 48 weeks)

HCV = hepatitis C virus; HCV-RNA = hepatitis C virus ribonucleic acid

a

The manufacturer packaging and dosage information does not specify a particular pegylated interferon (alfa-2a or alfa-2b) for either drug, though in trials conducted to obtain FDA approval, boceprevir was tested with pegylated interferon alfa-2b and telaprevir with pegylated interferon alfa-2a.

From: Introduction

Cover of Treatment for Hepatitis C Virus Infection in Adults
Treatment for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 76.
Chou R, Hartung D, Rahman B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.